Event-Free Survival as a Predictor of Overall Survival and Recurrence Burden of Patients with Non-Small Cell Lung Cancer Receiving Neoadjuvant Therapy
This study aims to examine the correlation between real-world EFS (rwEFS) and OS and to assess the clinical and economic burden associated with disease recurrence among patients with resected, stage II-III non-small cell lung cancer (NSCLC) received neoadjuvant therapy in the US.
Source: The Journal of Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Jessica Donington, Xiaohan Hu, Su Zhang, Yan Song, Ashwini Arunachalam, Diana Chirovsky, Chi Gao, Ari Lerner, Anya Jiang, James Signorovitch, Ayman Samkari Source Type: research
More News: Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Clinical Trials | Heart | Lung Cancer | Neoadjuvant Therapy | Non-Small Cell Lung Cancer | Study